Lewy Body Disease
A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)
Drugs by status
Phase 4 trials (12)
Phase 3 trials (5)
Phase 2 trials (20)
Phase 1 trials (7)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (20)
- Avid Radiopharmaceuticals
- Eli Lilly
- EIP Pharma, LLC
- Heptares Therapeutics Limited
- Sosei
- National Institutes of Health (NIH)
- Helse Fonna
- University of London
- Georgetown University
- Lund University
- University of Oslo
- Columbia University
- Worldwide Clinical Trials
- Helse Bergen
- SPARC
- University of Western Ontario
- The Florey Institute of Neuroscience and Mental Health
- Alzheimer's Association
- University of Stavanger
- NeuroActiva
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (3)